1. Moreno, JD. Mind Wars: Brain Research and National Defense. New York: Dana Press; 2006.
3. U.S. Food and Drug Administration. Important information for augmentation patients about Mentor Memory-Gel® silicone gel-filled breast implants; 2006; available at http://www.fda.gov/cdrh/pdf3/p030053d.pdf (last accessed 24 Jun 2008); U.S. Food and Drug Administration. Patient labeling for INAMED® silicone-filled breast implants; 2006; available at http://www.fda.gov/cdrh/pdf2/P020056d.pdf (last accessed 24 Jun 2008).
4. U.S. Food and Drug Administration. Guidance for industry: Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices; draft guidance; 2008; available at http://www.fda.gov/oc/op/goodreprint.html (last accessed 24 Jun 2008).
5. National Institutes of Health National Heart, Lung, Blood Institute Women’s Health Initiative; available at http://www.nhlbi.nih.gov/whi/ (last accessed 24 Jun 2008).
6. Juengst, E. The meaning of enhancement. In: Parens, E, ed. Enhancing Human Traits: Ethical and Social Implications. Washington, DC: Georgetown University Press; 1998;29–47.
7. Department of Health and Human Services, Agency for Healthcare Research and Quality. Short Stature: Criteria for Determining Disability in Infants and Children (Evidence Report/Technology Assessment 73); 2008; available at http://www.ahrq.gov/clinic/epcsums/shortsum.htm.
10. Apud, JA, Mattay, V, Chen, J, Kolachana, BS, Callicott, JH, Rasetti, R, et al. . Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology 2007;32:1011–20.
11. Berg, JW, Mehlman, MJ, Rubin, DB, Kodish, E. Making all the children above average: Ethical and regulatory concerns for pediatricians in pediatric enhancement research. Clinical Pediatrics 2009;48:472–80.
12. 45 C.F.R. § 46.111 (2008).
13. 45 C.F.R. § 46.111(b) (2008).
14. See note 11, Berg et al. 2009.
15. Castellanos, FX, Rapoport, JL. Effects of caffeine on development and behavior in infancy and childhood: A review of the published literature. Food and Chemical Toxicology 2002;40:1235–42.
16. Tauer, CA. The NIH trials of growth hormone for short stature. IRB: A Review of Human Subjects Research 1994;16:1–9.
17. Shah, S, Whittle, A, Wilfond, B, Gensler, G, Wendler, D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA 2004;291:476–82.
18. 45 C.F.R. § 46.407 (2008).
19. In a letter from Donald L. Rosenstein, Chair NIMH IRB, to Michael Gottesman, Deputy Director, March 5, 2004, the proposed protocol was called “Effects of a single dose of Dextroamphetamine in Attention Deficit Hyperactivity Disorder: A function Magnetic Resonance study”; available at http://www.hhs.gov/ohrp/panels/jreview01/irbreq.pdf (last accessed 20 Oct 2009).
20. 45 C.F.R. § 46.204(b) (2008).
21. See note 20, 45 C.F.R. 2008.
22. 45 C.F.R. § 46.111(a)(2) (2008).
23. Berg, J. Owning persons: The application of property theory to embryos and fetuses. Wake Forest Law Review 2005;40:159.
24. Parfit, D. Reasons and Persons. Oxford: Oxford University Press; 1986:351–79.
25. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research; 1979; available at http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.htm (last accessed 18 Feb 2008).
26. The FDA proposed regulations that would limit prisoners’ rights to participate in research, and prisoners initiated a lawsuit. Sun, M.Inmates sue to keep research in prisons. Science 1981;212:650–1. The FDA withdrew its proposed regulations and never reissued them.
28. See note 27, Office of Human Subjects Protections.
29. King, NMP, Robeson, R. Athlete or guinea pig? Sports and enhancement research. Studies in Ethics, Law and Technology 2007;1:1.
32. See note 1, Moreno 2006.
33. Human experimentation: An overview on Cold War era programs: Testimony before the Legislation and National Security Subcommittee, House Committee on Government Operations, United States General Accounting Office (Sept. 28, 1994) (Testimony of Assistant Comptroller General Frank C. Conahan); available at http://archive.gao.gov/t2pbat2/152601.pdf (last accessed 18 Feb 2008).
34. Report of the Senate Committee on Veterans’ Affairs, 103d Cong. 2d Sess., Is military research hazardous to veterans’ health? Lessons spanning half a century (Comm. Print S. Prt. 103-97); available at http://www.gulfweb.org/bigdoc/rockrep.cfm#hallucinogens (last accessed 18 Feb 2008).
35. 32 C.F.R. § 219.101(f) (2005).
36. 10 U.S.C. § 980 (2006); 21 C.F.R § 50.24 (2008).
37. Brown, KD. An ethical obligation to our service members: Meaningful benefits for informed consent violations. South Texas Law Review 2006;47:919.
40. McManus, J, Mehta, SG, McClinton, AR, De Lorenzo, RA, Baskin, TW. Informed consent and ethical issues in military medical research. Academic Emergency Medicine 2005;12:1120–6.